Healthcare Industry News: endoscope
News Release - March 15, 2013
Novadaq Announces Termination of Agreements With KCITORONTO, ONTARIO--(Healthcare Sales & Marketing Network) - Novadaq® Technologies Inc. ("Novadaq" or the "Company") (NDQ.TO)(NVDQ), a developer of clinically-relevant fluorescence imaging solutions for use in surgical and wound care procedures, today announced that Novadaq and Kinetic Concepts Inc. ("KCI") have terminated agreements that were signed in November 2011 related to the development, sales and marketing of the LUNA™ fluorescence imaging system which is used in wound care clinics. The termination is considered amicable - primarily relating to changing priorities - and neither company is required to compensate the other as a result of the change. All agreements with LifeCell, including those signed in November 2011 related to vascular surgery applications of SPY Elite®, remain active.
LUNA is Novadaq''s implementation of its core SPY imaging technology, productized primarily for use by wound care centers for diagnostic imaging. LUNA is used to assess vascular flow and perfusion in patients with non-healing wounds caused by vascular deficiencies.
"Termination of the agreements enables Novadaq to accelerate the launch of LUNA in diagnostic wound care imaging applications," commented Dr. Arun Menawat, President and CEO of Novadaq. "We have already tested commercial first generation LUNA systems in wound care clinics in the United States. These centers have reported that the use of LUNA provides therapeutic benefits to the patient and economic benefits to the clinic."
Dr. Menawat continued, "Novadaq has proven that we can successfully develop new applications for our core SPY imaging technology and that we can commercially launch products designed specifically for those applications, as we did with plastic reconstructive surgery before partnering that application. The process of commercializing LUNA begins at the upcoming Diabetic Foot Global Conference in Los Angeles, where on March 23rd Novadaq will participate in a LUNA workshop for wound care specialists."
Commenting on the medical value of visually assessing blood flow and tissue perfusion in patients susceptible to, or presenting with wounds, Dr. David Armstrong, DPM, MD, PhD, and Director of the Southern Arizona Limb Salvage Alliance, stated, "Adequate blood flow and tissue perfusion are critical to the healing of wounds in patients suffering from peripheral vascular diseases. Consequently, it is important to be able to adequately assess baseline perfusion at the onset of the wound and to perform serial assessments during the selection; implementation and monitoring of optimal wound treatment strategies. LUNA is the only technology currently available that clearly and reliably visually maps areas of adequate versus poor perfusion, and as a result, with LUNA, practitioners will be able to implement more effective wound treatment strategies which will positively enhance wound healing."
More than 10 million people in the United States suffer from peripheral arterial disease (PAD), and of these, approximately 10% have critical limb ischemia (CLI), which is the most severe form. Due to diabetes, advanced age, or poor nutrition status, CLI is associated with reduced blood flow to the extremities and can lead to formation of chronic ulcers, amputation and death. It is estimated that the disease accounts for approximately 2 million outpatient visits each year in the United States.
About Novadaq Technologies Inc.
Enabling medical professionals with clinically-relevant, innovative fluorescence imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is Novadaq''s global mission. SPY fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 60 peer-reviewed publications demonstrate that the use of SPY imaging during complex surgery, leads to fewer post-operative complications and lower hospital costs.
SPY Imaging Systems are United States Food and Drug Administration 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT®, combines the capabilities of SPY Imaging with high definition ("HD") visible light visualization offered by conventional endoscopes. Our unique business model of partnering with market-leading companies to drive adoption of our fluorescence imaging technology, while building our own commercial infrastructure is the cornerstone of our corporate strategy for growth.
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq''s current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, the Company''s strategy, strategic goals, research and development activities, research and clinical testing outcomes, taxes, capital expenditures, future operations, future financial position, future revenues/results, projected costs, prospects and plans and objectives of management.
Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings available at www.sedar.com, actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Novadaq Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.